Abstract

Objective: The aim of this study is to investigate the efficiency of a first-line molecular genetic evaluation approach, in children with deafness.

Methods: Patients who were found to have sensorineural hearing loss by age-appropriate audiological tests were selected for the molecular genetic evaluation. The molecular genetic evaluation was carried out with GJB2 gene sequence analysis and mtDNA m.1555A>G mutation Restriction Fragment Length Polymorphism (RFLP) analysis. Additionally, in a small group of patients, hearing loss Multiplex Ligation-dependent Probe Amplification (MLPA) analysis was done out to identify the possible role of copy number changes.

Results: In this Turkish cohort, which included 104 index patients and 78 relatives, 33 (31.7%) had Pathogenic/Likely Pathogenic variants. One or more GJB2 sequence variants were identified in 46 (44.1%) of the 104 index patients. The homozygous c.35delG mutation by itself explained the etiology in 24% of our ARNSHL group. In one (5%) of the 20 patients of MLPA group, a hemizygous deletion in POU3F4 gene was detected.

Conclusion: In our Turkish cohort, we applied a first-line molecular genetic evaluation approach using GJB2 gene sequence analysis and mtDNA m.1555A>G RFLP analysis. This approach revealed the genetic etiology of 44.1% of our index patients. Additionally, the results of hearing loss MLPA analysis revealed the limited role of copy number changes in this patient group. Furthermore, with a detailed genotype-phenotype association workup, 2 rare cases of Deafness with Palmoplantar Hyperkeratosis and Keratitis-Ichthyosis-Deafness syndrome were reported.

Keywords: Deafness, hearing loss, genetics, GJB2

Introduction

Hearing loss (HL) or hearing impairment, is a partial or total inability to hear. Hearing loss may be mild, moderate, moderate-to-severe, severe, or profound. Profound or total loss of hearing is defined as deafness. According to the World Health Organization (WHO), 466 million people in the world are affected by “disabling hearing loss” (more than 5% of the world’s population) and 34 million (7.2%) of these are children (1). The prevalence of disabling hearing loss in children is 1.7% worldwide and 0.9% in our region (2). Hearing loss in children can be classified by type (conductive/sensorineural/mixed/central), by degree (mild/moderate/moderate-to-severe/severe/profound), by configuration (high-frequency/low-frequency, bilateral/unilateral, symmetrical/asymmetrical, progressive/sudden, fluctuating/stable), by time of onset (prenatal/neonatal/postnatal), by etiology (congenital [genetic/non-genetic], acquired), and in terms of its influence on speech development (prelingual/postlingual) (3, 4).

Hearing loss can be due to environmental factors, genetic factors, or the combination of both. In developed countries, genetic factors are the leading cause of childhood HL. While 30% of all genetic HL cases are syndromic (SHL), the remaining 70% of the cases, where HL is the only feature, are non-syndromic (NSHL). The genetic causes of NSHL are generally associated with mutations in single genes (5). To date, more than 100 genes have been associated...
with non-syndromic hearing loss (6). The NSHL is a heterogeneous group of disorders since different mutations in the same gene can cause different types of hearing loss. Furthermore, some genes are associated with both the syndromic and the non-syndromic forms of HL (7). Autosomal-recessive NSHL (ARNSHL) accounts for 80%, autosomal dominant (ADNSHL) for 20%, X-linked for 1% of all NSHL while mitochondrial is rare (<1%). Most ARNSHL cases are prelingual, severe-to-profound, whereas ADNSHL cases are often postlingual and progressive (1).

The nomenclature for NSHL is defined by several abbreviations. “DFN” is used to indicate Non-syndromic deafness loci; the following A, B or X letters are added for the mode of inheritance (DFNA: autosomal dominant; DFNB: autosomal recessive; DFNX: X-linked) and the last number is for the gene in the order of gene mapping or discovery (8).

About 50% of the ARNSHL cases are associated with the DFNB1 locus. The GJB2 gene, which encodes the gap junction protein connexin 26 (Cx26), is the primarily associated gene for the DFNB1 locus. Mutations in another connexin gene, GJB6 (connexin 30/Cx30), can also cause DFNB1. The importance of connexin proteins in hearing loss comes from the role these proteins play in forming channels called gap junctions. The Cx26 gap junctions are formed among non-sensory epithelial cells and connective tissue cells, serving as a structural basis for recycling endolymphatic potassium ions (9). It was hypothesized that nonfunctional gap junctions cause elevated extracellular potassium concentration, extracellular accumulation of glutamate and the apoptosis of cochlear epithelial cells and outer hair cells (9).

Although mtDNA mutations are generally responsible for less than 1% of the disease, m.1555A>G mutation found in the 12S RNA gene of mitochondria is more common in the Far East countries. Studies conducted with Turkish patients have shown that it contributes by 1.8% (8).

In patients with hearing loss diagnostic approach starts with family history and physical examination. It is important to obtain at least three generations of family history and pedigree. This will give a clue of the type of inheritance, and as well help to identify the other affected individuals in the family. Because of the variable expressivity, it is necessary to be cautious against the additional symptoms associated with syndromic hearing loss that can manifest very mildly due to variable expression (10).

Audiometric testing is important in determining whether the hearing loss is unilateral or bilateral, and in determining which frequencies are more prominently lost. The physical examination, the audiologic phenotype, and the patient’s ethnicity are the most critical data that guide the selection of molecular genetic testing. It is controversial if genetic testing should be offered to non-syndromic children with unilateral hearing loss, in initial workup (11).

According to the consensus recommendations released by the International Pediatric Otalaryngology Group (IPOG), in the molecular genetic evaluation of children with bilateral sensorineural hearing loss, single gene analysis (GJB2/GJB6) or comprehensive genetic testing (next-generation sequencing gene panels) may be preferred, depending on the patient’s audiometric phenotype, ethnic origin and availability of tests (9).

IPOG emphasizes the importance of ethnic origin in determining the genetic testing strategy. As an example to this, even if GJB6 has been shown to contribute significantly to the etiology of the DFNB1 group, many studies have shown that GJB6 does not play a significant role in the Turkish population (10, 11). Furthermore, although mtDNA mutations are very rare (<1%) in the general population, they reach a frequency of 1.8% in the Turkish population (12).

In this report, we applied a first-line molecular genetic evaluation approach using GJB2 gene sequence analysis, mtDNA m.1555A>G mutation RFLP analysis in 182 Turkish patients suspected of ARNSHL. We evaluated the diagnostic rates of our approach and investigated variant frequencies associated with GJB2 in Turkey. The association between genotype and phenotypes was also analyzed.

Methods

Patient selection

The study was approved by the University of Health Sciences, Tepecik Training and Research Hospital, Ethics Committee (2019/2-18). Written informed consent was obtained from the parents or guardians of the children.

Patients were mostly referred by the Child Hearing Assessment Center of Tepecik Training and Research Hospital. Audiometric tests of patients were also performed in this center.

Patients who were found to have sensorineural hearing loss and no additional findings suggesting a syndromic hearing loss were included in the molecular genetic evaluation.

Audiological testing

Hearing thresholds were determined by age-appropriate auditory brainstem audiometry (Navigator pro, Bio-Logic Systems Corp, Mundelein, IL, USA), and when possible by tonal audiometry with warble tones presented through TDH 39 supra-aural headphones by means of a clinical audiometer (Madsen TM, Orbiter 922, GN Otometrics, Copenhagen, Denmark). In order to exclude any auditory neuropathy spectrum disorder, otoacoustic emissions were also tested by Oto-dynamics ILO 88 OAE system (Otodynamics Inc., Hatfield, Herts, UK). The degree of hearing loss was determined based on The American Speech-Language-Hearing Association (ASHA) criteria (4).
GJB2 sequence analysis
Genomic DNA was extracted from peripheral blood samples according to the manufacturer’s protocols. The entire coding and flanking region of GJB2 were amplified by polymerase chain reaction (PCR) in two overlapping segments:

Cx26 1F: 5’-TGT AAA ACG ACG GCC AGT CAT TCG TCT TTT CCC GAG CA-3’

Cx26 2R: 5’-CAG GAA ACA GCT ATG ACC AGC CTT CGA TGC GGA CCT-3’

Cx26 3F: 5’-TGT AAA ACG ACG GCC AGT ACC GGA GAC ATG AGA AGA AG-3’

Cx26 4R: 5’-CAG GAA ACA GCT ATG ACC GTT GCA TTT AAG GTC AGA ATC-3’

Polymerase chain reaction conditions were as follows: 100 ng of genomic DNA was amplified in a 10 μl reaction volume. An initial denaturation step of 10 min at 95°C was followed by 35 cycles of 95°C for 30 secs, 60°C for 45 secs and 72°C for one min. And one final cycle of 72°C for 7 min. PCR products were purified (ExoSAP-IT, Thermo Fisher Scientific Inc., MA, USA) prior to cycle sequencing. For sequencing, the ABI PRISM Big Dye Primer v3.0 Cycle Sequencing Ready Reaction kit was used (Big Dye Primer Cycle Sequencing Ready Reaction Kit, Applied Biosystems Inc., CA, USA) and the reaction products were analyzed on an ABI 3500 (ABI 3500 Genetic Analyzer, Applied Biosystems Inc., CA, USA) automated sequencer. Sequence chromatograms were obtained using SeqScape software (SeqScape V2, Applied Biosystems Inc., CA, USA).

Detected variants were analyzed using the ClinVar database (12) and the recommendations for variant interpretation by the American College of Medical Genetics and Genomics (ACMG) (13, 14).

mtDNA A1555G mutation analysis
To detect A1555G mtDNA mutation, the PCR was used to amplify the genomic region covering the mutation. To discriminate wild type and mutant sequences, a restriction endonuclease reaction was used. Digestion products were then electrophoresed through 12% agarose gels and fragment sizes visualized by autoradiography. To identify the A1555G mutation, a 566 bp PCR product was digested with HaeIII enzyme (HaeIII, New England Biolabs, Ipswich, MA, USA). If the A to G mutation at position 1555 was present, a 111 bp fragment was cleaved into 91 and 20 bp fragments.

Hearing loss Multiplex Ligation-dependent Probe Amplification (MLPA) analysis
To identify copy number changes in a small group of patients (20 patients), P163 probemix (SALSA MLPA P163 GJB-WFS1 Probemix, MRC-Holland BV, Amsterdam, the Netherlands) was used. The MLPA probe mix was containing probes for all exons of GJB2 and GJB6 genes, exon 1 and upstream of the POU3F4 gene and eight exons of the WFS1 gene. The PCR products obtained as a result of MLPA reaction were run on the Applied Biosystems 3500 capillary electrophoresis device. As a result of the process, peak images and peak areas of the probes of each sample were obtained in the CEQ program. Excel based Coffalyser (Coffalyser, MRC-Holland BV, Amsterdam, the Netherlands) program was used for analysis.

Results
Characteristics of the patients
The patients’ audiometric testing results varied from bilateral mild hearing loss to bilateral profound hearing loss. Of the 25 patients with homozygous c.35delG mutation, 21 were evaluated by audiometric testing. Of these 21 patients, 13 (62%) had profound hearing loss, seven (33%) had moderately severe/severe hearing loss and one (5%) had moderate hearing loss. While 12 of these 21 patients were male, nine were female.

Sequence variants detected by GJB2 sequence analysis
A total number of 182 samples (104 index patients and their 78 relatives) were analyzed by GJB2 sequencing analysis.

One or more GJB2 sequence variants were detected in 46 (44.1%) of the 104 index patients. Of these 46 patients, 33 (31.7%) had pathogenic/likely pathogenic variants, six (5.7%) had benign variants and seven (6.7%) had variants of unknown significance (VUS).

In 46 (44.2%) patients with sequence variants, homozygous c.35delG (p.Gly12ValfsTer2) was the most frequent variant, detected in 25 (24%) index patients. Other frequent variants were c.457G>A (p.Val153Ile), c.487A>G (p.Met163Val) and c.478G>A (p.Gly160Ser), detected in five (4.8%), three (2.8%) and two (1.9%) index patients, respectively.

Frequent variants

- c.35delG (p.Gly12ValfsTer2)

In 25 of the index patients, homozygous c.35delG mutation was detected. This mutation alone was explaining 24% of the etiology of our ARSNHL group. Patients with this homozygous mutation were mainly suffering from moderate to profound hearing loss.

- c.457G>A (p.Val153Ile)

In five of the index patients, there was a heterozygous c.457G>A variant. This variant was listed as benign in the ClinVar database.

- c.487A>G (p.Met163Val)

A heterozygous c.487G>A variant was detected in three index patients and in two unaffected mothers. This variant was interpreted as VUS (PM1, PP2, and PP3) according to the ACMG guidelines and it was listed as VUS in the ClinVar database.
Two sibs (Patients #11 and #12) were detected to carry heterozygous c.478G>A variant. This variant was listed as "conflicting interpretations of pathogenicity" in the ClinVar database and it was interpreted as VUS (PM1, PP2, and PP3) according to the ACMG guidelines. The variant was associated with autosomal recessive and autosomal dominant SNHL.

**Rare variants**

- **c.670A>C** (p.Lys224Gln)

  A homozygous c.670A>C variant was detected in patient #14. Her parents were heterozygous for the variant. This variant was interpreted as VUS (PP2 and PP3) according to the ACMG guidelines and it was listed as VUS in the ClinVar database.

- **c.511G>A** (p.Ala171Thr)

  Patient #38 was carrying the c.511G>A variant in heterozygous form. The variant was interpreted as VUS (PM1 and PP2) according to the ACMG guidelines and it was listed as VUS in the ClinVar database.

- **c.5_9delinsCAT** (p.Asp2AlafsTer45)

  In patient #157 a heterozygous c.5_9delinsCAT variant was detected. The patient was consulted for hearing loss and palmoplantar hyperkeratosis. This variant was causing a frameshift in GJB2 gene translation. The variant was interpreted as likely pathogenic (PVS1 and PP2) according to the ACMG guidelines and it was not listed in databases. We suggest this variant as a novel mutation.

- **c.314_329del** (p.Lys105ArgfsTer2)

  Patient #163 was carrying the c.314_329del variant in the heterozygous state. This was a frameshift variant. The variant was interpreted as pathogenic (PVS1, PM1, PM2, and PP5) according to the ACMG guidelines and it was listed as pathogenic in the ClinVar database.

- **c.263C>T** (p.Ala88Val)

  The variant was detected in patient #177 in the heterozygous state and it was listed as pathogenic in the ClinVar database. The patient was a 1-month-old girl with dysmorphic features (frontal bossing and down-slanting palpebral fissures), congenital ichthyosis, keratoconjunctivitis sicca in eyes and nail dystrophy. The patient was diagnosed as Keratitis-Ichthyosis-Deafness syndrome (KID).

- **c.551G>C** (p.Arg184Pro)

  Patient #135 was carrying the c.551G>C variant in the heterozygous state. The variant was interpreted as VUS (PM2, PP2, PP3, and PP5) according to the ACMG guidelines; however, it was listed as pathogenic in the ClinVar database.

**Compound heterozygous variants**

- **c.35delG/ c.47A>G**

  Patient #18 was carrying c.35delG/ c.47A>G variants in the compound heterozygous state. Both variants were known as pathogenic mutations. Both parents were carrying each of the variants in the heterozygous state.

- **c.35delG/ c.269T>C**

  The c.35delG/ c.269T>C variants were detected in patient #43 in the compound heterozygous state. The c.35delG was a known pathogenic mutation. c.269T>C was listed pathogenic in the ClinVar database.

- **c.35delG/ c.71G>A**

  Two sibs (#166 and #167) were carrying the c.35delG/ c.71G>A variants in the compound heterozygous state. The c.35delG was a known pathogenic mutation. The c.71G>A was a frameshift variant with Pathogenic records in the ClinVar database.

- **c.79G>A/ c.341A>G**

  Patient #2 and her unaffected mother were carrying c.79G>A/ c.341A>G variants in compound heterozygous form (-cis state). Both variants were listed as benign in ClinVar.

**mtDNA A1555G mutation analysis**

No mtDNA A1555G mutation was detected in the index patient group (104 patients).

**Hearing loss MLPA analysis**

In 58 patients no variants were detected. Twenty of the 58 patients were selected for MLPA P163 GJB-WFS1 analysis. In one (5%) of the 20 patients, a hemizygous deletion in POU3F4 gene was detected.

Audiometry results and molecular genetic findings are summarized in Table 1.

**Discussion**

A 70% of genetic HL, is NSHL. The genetic causes of NSHL are generally associated with mutations in single genes. According to the consensus recommendations released by IPOG, in the molecular genetic evaluation of NSHL, selection of the approach (GJB2/GJB6 single gene analysis vs multigene next-generation sequencing panels) should depend on the patient’s audiometric phenotype, ethnic origin, and availability of the tests. As for the Turkish population, several studies showed that GJB6 does not play a significant role in the Turkish population (10, 11). Thus, we applied a first-line molecular genetic evaluation approach using GJB2 gene sequence analysis and mtDNA m.1555A>G RFLP analysis in patients suspected of ARNSHL. We also investigated the role of copy number changes by MLPA analysis in a subgroup of patients in which GJB2 mutation was not detected.
Table 1. Patients’ age, degree of hearing loss, molecular genetic findings and results of family investigations

<table>
<thead>
<tr>
<th>Patient #</th>
<th>Family #</th>
<th>Age</th>
<th>Degree of SNHL</th>
<th>Cochlear implant</th>
<th>GJB2 variant</th>
<th>Protein Change</th>
<th>Status</th>
<th>Family Investigations (ACMG/ClinVar)</th>
</tr>
</thead>
<tbody>
<tr>
<td>15</td>
<td>14</td>
<td>9</td>
<td>Bilateral Profound</td>
<td>-</td>
<td>c.35delG</td>
<td>p.Gly12ValfsTer2</td>
<td>Homo.</td>
<td>Parents are heterozygous for each of the mutations. Pathogenic (Pathogenic/Pathogenic)</td>
</tr>
<tr>
<td>40</td>
<td>25</td>
<td>7</td>
<td>Bilateral Profound</td>
<td>Right</td>
<td>c.35delG</td>
<td>p.Gly12ValfsTer2</td>
<td>Homo.</td>
<td>Pathogenic (Pathogenic/Pathogenic)</td>
</tr>
<tr>
<td>45</td>
<td>30</td>
<td>12</td>
<td>Right Moderately Severe/Left Severe</td>
<td>-</td>
<td>c.35delG</td>
<td>p.Gly12ValfsTer2</td>
<td>Homo.</td>
<td>Parents are heterozygous for each of the mutations. Pathogenic (Pathogenic/Pathogenic)</td>
</tr>
<tr>
<td>60</td>
<td>39</td>
<td>12</td>
<td>Right Moderate/ Left Moderately Severe</td>
<td>-</td>
<td>c.35delG</td>
<td>p.Gly12ValfsTer2</td>
<td>Homo.</td>
<td>#60 and #61 are sibs. Both have SNHL. Pathogenic (Pathogenic/Pathogenic)</td>
</tr>
<tr>
<td>61</td>
<td>39</td>
<td>16</td>
<td>Right Moderately Severe/Left Severe</td>
<td>-</td>
<td>c.35delG</td>
<td>p.Gly12ValfsTer2</td>
<td>Homo.</td>
<td>#60 and #61 are sibs. Both have SNHL. Pathogenic (Pathogenic/Pathogenic)</td>
</tr>
<tr>
<td>62</td>
<td>40</td>
<td>7</td>
<td>Bilateral Profound</td>
<td>Right</td>
<td>c.35delG</td>
<td>p.Gly12ValfsTer2</td>
<td>Homo.</td>
<td>Pathogenic (Pathogenic/Pathogenic)</td>
</tr>
<tr>
<td>66</td>
<td>44</td>
<td>30</td>
<td>NDA</td>
<td>-</td>
<td>c.35delG</td>
<td>p.Gly12ValfsTer2</td>
<td>Homo.</td>
<td>#66 and #79 are sibs. Both have SNHL. Pathogenic (Pathogenic/Pathogenic)</td>
</tr>
<tr>
<td>79</td>
<td>44</td>
<td>28</td>
<td>NDA</td>
<td>-</td>
<td>c.35delG</td>
<td>p.Gly12ValfsTer3</td>
<td>Homo.</td>
<td>#66 and #79 are sibs. Both have SNHL. Pathogenic (Pathogenic/Pathogenic)</td>
</tr>
<tr>
<td>68</td>
<td>46</td>
<td>14</td>
<td>NDA</td>
<td>Right/Left</td>
<td>c.35delG</td>
<td>p.Gly12ValfsTer2</td>
<td>Homo.</td>
<td>Pathogenic (Pathogenic/Pathogenic)</td>
</tr>
<tr>
<td>69</td>
<td>48</td>
<td>5</td>
<td>Bilateral Moderately severe</td>
<td>Right/Left</td>
<td>c.35delG</td>
<td>p.Gly12ValfsTer2</td>
<td>Homo.</td>
<td>Parents are heterozygous for each of the mutations. Pathogenic (Pathogenic/Pathogenic)</td>
</tr>
<tr>
<td>87</td>
<td>57</td>
<td>1</td>
<td>Bilateral Profound</td>
<td>-</td>
<td>c.35delG</td>
<td>p.Gly12ValfsTer2</td>
<td>Homo.</td>
<td>Pathogenic (Pathogenic/Pathogenic)</td>
</tr>
<tr>
<td>88</td>
<td>58</td>
<td>9</td>
<td>Bilateral Profound</td>
<td>Right</td>
<td>c.35delG</td>
<td>p.Gly12ValfsTer2</td>
<td>Homo.</td>
<td>Parents are heterozygous for each of the mutations. Pathogenic (Pathogenic/Pathogenic)</td>
</tr>
<tr>
<td>106</td>
<td>65</td>
<td>47</td>
<td>Bilateral Moderate</td>
<td>-</td>
<td>c.35delG</td>
<td>p.Gly12ValfsTer2</td>
<td>Homo.</td>
<td>Pathogenic (Pathogenic/Pathogenic)</td>
</tr>
<tr>
<td>102</td>
<td>67</td>
<td>7</td>
<td>Bilateral Profound</td>
<td>Right</td>
<td>c.35delG</td>
<td>p.Gly12ValfsTer2</td>
<td>Homo.</td>
<td>Parents are heterozygous for each of the mutations. Pathogenic (Pathogenic/Pathogenic)</td>
</tr>
<tr>
<td>115</td>
<td>74</td>
<td>4</td>
<td>Bilateral Profound</td>
<td>Right/Left</td>
<td>c.35delG</td>
<td>p.Gly12ValfsTer2</td>
<td>Homo.</td>
<td>Parents are heterozygous for each of the mutations. Pathogenic (Pathogenic/Pathogenic)</td>
</tr>
<tr>
<td>122</td>
<td>78</td>
<td>35</td>
<td>NDA</td>
<td>-</td>
<td>c.35delG</td>
<td>p.Gly12ValfsTer2</td>
<td>Homo.</td>
<td>Pathogenic (Pathogenic/Pathogenic)</td>
</tr>
<tr>
<td>126</td>
<td>82</td>
<td>28</td>
<td>Bilateral Profound</td>
<td>-</td>
<td>c.35delG</td>
<td>p.Gly12ValfsTer2</td>
<td>Homo.</td>
<td>Mother (#126), father (#127) and daughter (#133) are homozygous Pathogenic (Pathogenic/Pathogenic)</td>
</tr>
<tr>
<td>Patient #</td>
<td>Family #</td>
<td>Age</td>
<td>Degree of SNHL</td>
<td>Cochlear implant</td>
<td>GJB2 variant</td>
<td>Protein Change</td>
<td>Status</td>
<td>Family Investigations (ACMG/ClinVar)</td>
</tr>
<tr>
<td>-----------</td>
<td>----------</td>
<td>-----</td>
<td>----------------</td>
<td>------------------</td>
<td>--------------</td>
<td>----------------</td>
<td>--------</td>
<td>-----------------------------------</td>
</tr>
<tr>
<td>127</td>
<td>82</td>
<td>30</td>
<td>Bilateral Profound</td>
<td>-</td>
<td>c.35delG</td>
<td>p.Gly12ValfsTer2</td>
<td>Homo.</td>
<td>Pathogenic (Pathogenic/Pathogenic)</td>
</tr>
<tr>
<td>133</td>
<td>82</td>
<td>4</td>
<td>Bilateral Profound</td>
<td>-</td>
<td>c.35delG</td>
<td>p.Gly12ValfsTer2</td>
<td>Homo.</td>
<td>Pathogenic (Pathogenic/Pathogenic)</td>
</tr>
<tr>
<td>137</td>
<td>89</td>
<td>9</td>
<td>Right Moderate/Left Severe</td>
<td>-</td>
<td>c.35delG</td>
<td>p.Gly12ValfsTer2</td>
<td>Homo.</td>
<td>Pathogenic (Pathogenic/Pathogenic)</td>
</tr>
<tr>
<td>138</td>
<td>89</td>
<td>4</td>
<td>Bilateral Severe</td>
<td>-</td>
<td>c.35delG</td>
<td>p.Gly12ValfsTer2</td>
<td>Homo.</td>
<td>Pathogenic (Pathogenic/Pathogenic)</td>
</tr>
<tr>
<td>146</td>
<td>95</td>
<td>?</td>
<td>Bilateral Profound</td>
<td>Right</td>
<td>c.35delG</td>
<td>p.Gly12ValfsTer2</td>
<td>Homo.</td>
<td>Pathogenic (Pathogenic/Pathogenic)</td>
</tr>
<tr>
<td>151</td>
<td>97</td>
<td>4</td>
<td>Bilateral Profound</td>
<td>Right/Left</td>
<td>c.35delG</td>
<td>p.Gly12ValfsTer2</td>
<td>Homo.</td>
<td>Pathogenic (Pathogenic/Pathogenic)</td>
</tr>
<tr>
<td>18</td>
<td>11</td>
<td>5</td>
<td>Right Severe/Left Moderate</td>
<td>-</td>
<td>c.35delG</td>
<td>p.Gly12ValfsTer2</td>
<td>Comp. Het.</td>
<td>Pathogenic (Pathogenic/Pathogenic)</td>
</tr>
<tr>
<td>43</td>
<td>28</td>
<td>5</td>
<td>Bilateral Moderately severe</td>
<td>-</td>
<td>c.35delG</td>
<td>p.Gly12ValfsTer2</td>
<td>Comp. Het.</td>
<td>Pathogenic (Pathogenic/Pathogenic)</td>
</tr>
<tr>
<td>166</td>
<td>110</td>
<td>2</td>
<td>Bilateral Moderate</td>
<td>-</td>
<td>c.35delG</td>
<td>p.Gly12ValfsTer2</td>
<td>Comp. Het.</td>
<td>Pathogenic (Pathogenic/Pathogenic)</td>
</tr>
<tr>
<td>167</td>
<td>110</td>
<td>3</td>
<td>Bilateral Moderate</td>
<td>-</td>
<td>c.35delG</td>
<td>p.Gly12ValfsTer2</td>
<td>Comp. Het.</td>
<td>Pathogenic (Pathogenic/Pathogenic)</td>
</tr>
</tbody>
</table>
One or more GJB2 sequence variants were detected in 46 (44.2%) of the 104 index patients. Among them, 33 (31.7%) had pathogenic/likely pathogenic variants:

**Homozygous and compound heterozygous pathogenic variants**

In 25 (24%) index patients, homozygous c.35delG was detected and it was the most frequent variant. This covered 75.7% of all GJB2 associated pathogenic/likely Pathogenic variants. In the GJB2 gene, most of the pathologic mutations are located in exon 2, and the c.35delG mutation in this exon is the most frequent cause of NSHL in Turkey and in the world (15). Atik et al. (16) investigated the role of GJB2 and Mendelian exome sequencing panel in ARNSHL, and found 24.13% GJB2 associated homozygous or compound heterozygous causative mutations. Tekin et al. (12) reported that they have found the c.35delG allele in 68 (22.1%) of 308 chromosomes. With our data and previously reported ratios, we suggest that c.35delG mutation alone explains around 25% of the etiology in the ARSNHL group. Of the

---

**Table 1. Patients’ age, degree of hearing loss, molecular genetic findings and results of family investigations (continued)**

<table>
<thead>
<tr>
<th>Patient #</th>
<th>Family #</th>
<th>Age</th>
<th>Degree of SNHL</th>
<th>Cochlear implant</th>
<th>GJB2 variant</th>
<th>Protein Change</th>
<th>Status</th>
<th>Family Investigations (ACMG/ClinVar)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7</td>
<td>3</td>
<td>7</td>
<td>Bilateral Moderately severe</td>
<td>-</td>
<td>c.487A&gt;G</td>
<td>p.Met163Val</td>
<td>Het.</td>
<td>His mother has the same mutation, with NO SNHL. VUS (VUS/VUS)</td>
</tr>
<tr>
<td>10</td>
<td>13</td>
<td>11</td>
<td>Bilateral Moderate</td>
<td>-</td>
<td>c.487A&gt;G</td>
<td>p.Met163Val</td>
<td>Het.</td>
<td>Her mother has the same mutation, with NO SNHL. VUS (VUS/VUS)</td>
</tr>
<tr>
<td>33</td>
<td>18</td>
<td>15</td>
<td>Right Moderate/ Left Severe</td>
<td>-</td>
<td>c.487A&gt;G</td>
<td>p.Met163Val</td>
<td>Het.</td>
<td>VUS (VUS/VUS)</td>
</tr>
<tr>
<td>11</td>
<td>6</td>
<td>8</td>
<td>Bilateral Moderate</td>
<td>-</td>
<td>c.478G&gt;A</td>
<td>p.Gly160Ser</td>
<td>Het.</td>
<td>#11 and #12 are sibs. Both have SNHL. VUS (VUS/VUS)</td>
</tr>
<tr>
<td>12</td>
<td>6</td>
<td>6</td>
<td>Bilateral Moderately severe</td>
<td>-</td>
<td>c.478G&gt;A</td>
<td>p.Gly160Ser</td>
<td>Het.</td>
<td>#11 and #12 are sibs. Both have SNHL. VUS (VUS/VUS)</td>
</tr>
<tr>
<td>2</td>
<td>1</td>
<td>7</td>
<td>Bilateral Profound</td>
<td>-</td>
<td>c.79G&gt;A</td>
<td>p.Val27Ile</td>
<td>Het.</td>
<td>His mother has the same mutations, with NO SNHL. Benign (Benign/Benign)</td>
</tr>
<tr>
<td>14</td>
<td>10</td>
<td>6</td>
<td>Bilateral Moderate</td>
<td>-</td>
<td>c.670A&gt;C</td>
<td>p.Lys224Gln</td>
<td>Homo.</td>
<td>Parents are heterozygous for each of the mutations. VUS (VUS/VUS)</td>
</tr>
<tr>
<td>38</td>
<td>23</td>
<td>17</td>
<td>NDA</td>
<td>-</td>
<td>c.511G&gt;A</td>
<td>p.Ala17Thr</td>
<td>Het.</td>
<td>VUS (VUS/VUS)</td>
</tr>
<tr>
<td>157</td>
<td>101</td>
<td>73</td>
<td>NDA</td>
<td>-</td>
<td>c.5_9 delinsCAT</td>
<td>p.Asp2AlafTer45</td>
<td>Het.</td>
<td>Novel Pathogenic (Pathogenic/-)</td>
</tr>
<tr>
<td>163</td>
<td>107</td>
<td>7</td>
<td>NDA</td>
<td>-</td>
<td>c.314_329del</td>
<td>p.Lys105ArgfTer2</td>
<td>Het.</td>
<td>Pathogenic (Pathogenic/Pathogenic)</td>
</tr>
<tr>
<td>135</td>
<td>87</td>
<td>7</td>
<td>Bilateral Moderately severe</td>
<td>-</td>
<td>c.551G&gt;C</td>
<td>p.Arg184Pro</td>
<td>Het.</td>
<td>Pathogenic (VUS/Pathogenic)</td>
</tr>
<tr>
<td>92</td>
<td>60</td>
<td>5</td>
<td>Bilateral Profound</td>
<td>Left WT</td>
<td>-</td>
<td>-</td>
<td>Hemizygous deletion POU3F4</td>
<td></td>
</tr>
</tbody>
</table>

Het: Heterozygous; Homo: Homozygous; SNHL: Sensorineural hearing loss; NDA: No data available; VUS: Variant of unknown significance
remaining eight patients with pathogenic/likely pathogenic variants, four patients were carrying pathogenic/likely pathogenic variants in (compound) heterozygous state along with c.35delG (c.35delG/ c.47A>G, c.35delG/ c.269T>C, c.35delG/ c.71G>A). The c.47A>G, c.269T>C and c.71G>A mutations were previously reported pathogenic variants that were associated with ARNSHL.

**Heterozygous pathogenic variants**

Four patients were carrying the c.5_9delinsCAT, c.314_329del, c.263C>T and c.551G>C variants in heterozygous state. In GJB2, variants detected in heterozygote state often create controversy in terms of the probability of autosomal dominant inheritance. The literature and databases were investigated against the probability that these variants were autosomal dominant. The heterozygous c.5_9delinsCAT variant was detected in a patient with hearing loss and palmoplantar hyperkeratosis (#157). The variant was not listed in databases. It was causing a frameshift and it was interpreted as “likely pathogenic” according to the ACMG guideline (PVS1, PM2, PM2). Since it was not previously reported and family data were not available, it is not possible to determine whether this variant is a dominant or a recessive mutation. However, we report this variant as a novel pathogenic mutation. The c.314_329del (p.Lys105ArgfsTer2) variant was found in patient #163 in heterozygous form. It was listed as pathogenic and associated with autosomal recessive SNHL in ClinVar. However, another mutation in the same amino acid position (c.313_326del [p.Lys105GlyfsTer5]) was reported to be associated with both autosomal recessive and autosomal dominant SNHL (17). Thus, we suggest that this variant in our patient may be causing autosomal dominant SNHL. The c.263C>T was detected in patient #177 in heterozygous state. The variant was a previously known pathogenic mutation. It was previously associated with keratitis-ichthyosis-deafness (KID) syndrome in heterozygous state and suggested that the c.263C>T mutation produced enhanced hemichannel activity, resulting in accelerated cell death that explains the etiology of the KID syndrome (16).

In our patient the c.551G>C variant was also listed as pathogenic and associated with ARNSHL in ClinVar. This mutation was previously reported in the heterozygous state in NSHL patients and the pathogenic effect was not concluded (22). In our patient, however, it was detected in homozygous state, and parents were carriers. As a result, the clinical significance of the c.670A>C variant is still uncertain. The c.551G>C variant was detected in patient #135 in heterozygous state. The variant was previously identified in two individuals with normal hearing (22). Thus, we suggest that the effect of this variant is controversial.

**Copy number changes**

Although the point mutations cover most of the genetic defects in ARSNHL, copy number changes were also identified (23). In Patient #5, a hemizygous deletion covering the POU3F4 gene was detected. Microdeletions covering the POU3F4 gene have been described as causative for the most common form of X-linked NSHL (24). In one (5%) of the 20 patients analyzed with MLPA, we detected a deletion. This data contributes to the role of copy number changes in NSHL etiology.

**Patients with no variants and patients with benign variants**

In the 58 patients with no variants and six patients with benign variants, the molecular genetic etiology remained unsolved. Additional molecular genetic studies should be planned for these 64 patients and even for the seven patients with VUS. We suggest that this second step approach can be carried out with multigene next-generation sequencing (NGS) panels or with whole exome/genome sequencing (WES/WGS).

**Clinical diversity**

The clinical effects of Cx26 mutations are associated with hearing loss at different levels of severity. However, mutations can also cause deafness associated with skin diseases. Furthermore, these skin diseases are associated with specific mutations in the same gene. Shuja et al. (25) suggested that unique channel activities are influenced by each class of mutation. In this report, we present two patients with additional skin diseases. Patient #157 had hearing loss and palmoplantar hyperkeratosis and patient #177 was diagnosed with keratitis-ichthyosis-deafness (KID) syndrome.
Conclusion
In this Turkish cohort of 104 index patients and 78 relatives, 33 (31.7%) had pathogenic/likely pathogenic variants. The homozygous c.35delG mutation alone explained 24% of the etiology in our ARSNHL group. Distinct mutations in Cx26 can cause deafness associated with skin diseases. As an example of these patients, we reported two patients with deafness with palmo-plantar hyperkeratosis and KID syndrome.

Ethics Committee Approval: Ethics committee approval was received for this study from University of Health Sciences, Tepecik Training and Research Hospital (2019/2-18).

Informed Consent: Written informed consent was obtained from the parents of the patients.

Peer-review: Externally peer-reviewed.


Conflict of Interest: The authors have no conflicts of interest to declare.

Financial Disclosure: The authors declared that this study has received no financial support.

References